Qamzova is a drug owned by Nanjing Delova Biotech Co Ltd. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 19, 2040. Details of Qamzova's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12059423 | Meloxicam composition, pharmaceutical preparation and preparation method and use thereof |
Jul, 2040
(15 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Qamzova is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qamzova's family patents as well as insights into ongoing legal events on those patents.
Qamzova's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qamzova's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 19, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qamzova Generic API suppliers:
Meloxicam is the generic name for the brand Qamzova. 25 different companies have already filed for the generic of Qamzova, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Qamzova's generic
Alternative Brands for Qamzova
There are several other brand drugs using the same active ingredient (Meloxicam) as Qamzova. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Avondale Pharms |
| |
| Axsome |
| |
| Baudax |
| |
| Heron Theraps Inc |
| |
| Iceutica Operations |
| |
| Tersera |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Meloxicam, Qamzova's active ingredient. Check the complete list of approved generic manufacturers for Qamzova
About Qamzova
Qamzova is a drug owned by Nanjing Delova Biotech Co Ltd. Qamzova uses Meloxicam as an active ingredient. Qamzova was launched by Nanjing Delova in 2025.
Approval Date:
Qamzova was approved by FDA for market use on 22 April, 2025.
Active Ingredient:
Qamzova uses Meloxicam as the active ingredient. Check out other Drugs and Companies using Meloxicam ingredient
Dosage:
Qamzova is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/ML (30MG/ML) | SOLUTION | Prescription | INTRAVENOUS |